AFP
ALXN

Ausdal Financial Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Ausdal Financial Partners’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-2
Closed – – 1116
2015
Q4 		$0 Buy
+2
New +$349 ﹤0.01% 1342

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Ausdal Financial Partners's ALXN Position: Q1 2016 in Review

Ausdal Financial Partners sold out of Alexion Pharmaceuticals (ALXN) in Q1 2016, closing a stake of 2 shares.

Ausdal Financial Partners first reported a position in ALXN in Q4 2015 and held it in 1 quarter. The position peaked at $0 in Q4 2015. 518 funds tracked by Wall St. Rank hold ALXN as of Q1 2016.

  • Ausdal Financial Partners reported no remaining Alexion Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Ausdal Financial Partners sold 2 Alexion Pharmaceuticals shares in Q1 2016.
  • Ausdal Financial Partners first reported a position in Alexion Pharmaceuticals in Q4 2015 and held it in 1 quarter.
  • Ausdal Financial Partners's Alexion Pharmaceuticals position peaked at $0 in Q4 2015.
  • 518 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2016.

Based on Ausdal Financial Partners's 13F filing for Q1 2016, filed 5 May 2016.